KEAP1 and cardiomyopathy: As ZJ01 is an effective Keap1–Nrf2 PPI inhibitor, we speculated ZJ01 might inhibit LPS-induced cardiomyopathy through disrupting Keap1–Nrf2 PPI which could induce Nrf2 nuclear accumulation and thus blocking oxidative and inflammatory signalling.